<DOC>
	<DOCNO>NCT00112736</DOCNO>
	<brief_summary>Erlotinib temsirolimus may stop growth tumor cell block enzymes need cell growth . This phase I/II trial study side effect best dose temsirolimus give together erlotinib see well work treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Erlotinib Temsirolimus Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To define maximum tolerate dose ( MTD ) OSI-774 ( erlotinib ; Tarceva ) combination CCI-779 ( temsirolimus ) patient recurrent malignant glioma take enzyme-inducing anti-epileptic drug ( EIAEDs ) . ( Phase I ) II . To characterize safety profile OSI-774 ( erlotinib ) CCI-779 ( temsirolimus ) . ( Phase I ) III . To characterize pharmacokinetics OSI-774 ( erlotinib ) CCI-779 ( temsirolimus ) . ( Phase I ) IV . To determine efficacy OSI-774 ( erlotinib ) CCI-779 ( temsirolimus ) patient recurrent malignant glioma measure 6-month progression-free survival . ( Phase II ) SECONDARY OBJECTIVES : I . Overall progression-free survival . ( Phase II ) II . Response . ( Phase II ) TERTIARY OBJECTIVES : I . To explore association response treatment molecular phenotype tumor . ( Phase II ) II . Determine whether OSI-774 ( erlotinib ) CCI-779 ( temsirolimus ) inhibit EGFR mTOR PI3K-AKT-mTOR RAS-ERK signal pathway tumor specimens take malignant glioma patient undergoing surgery . ( Phase II ) III . Tumor concentration OSI-774 ( erlotinib ) CCI-779 ( temsirolimus ) . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study temsirolimus follow phase II study . Patients stratify accord study phase ( I vs II ) , histology study enrollment ( glioblastoma multiforme gliosarcoma v anaplastic glioma ) , preoperative candidacy ( yes v ) , presence measurable evaluable disease ( yes v ) . PHASE I : Patients receive oral erlotinib daily day 1-28 temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos temsirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PHASE II : Patients receive temsirolimus MTD erlotinib phase I . PHASE II ( preoperative component ) : Patients surgical candidate may opt undergo surgical resection tumor . Beginning 5-7 day surgery , patient receive oral erlotinib daily surgery . Patients also receive temsirolimus IV 30 minute MTD undergo surgical resection tumor 3-24 hour later . Beginning 2-4 week surgery , patient receive temsirolimus MTD erlotinib phase I . PROJECTED ACCRUAL : A total 3-24 patient accrued phase I portion study within 1-8 month . A total 50 patient ( 32 patient glioblastoma multiforme 18 anaplastic glioma ) accrue phase II portion study within 8-12 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histologically prove intracranial glioblastoma multiforme ( GBM ) gliosarcoma ( GS ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant astrocytoma otherwise specify ( NOS ) eligible protocol ; patient eligible original histology lowgrade glioma subsequent histological diagnosis malignant glioma make All patient must sign informed consent indicate aware investigational nature study ; patient must sign authorization release protect health information ; patient must register Adult Brain Tumor Consortium ( ABTC ) Central Office database prior treatment study drug Patients must life expectancy &gt; 8 week Patients must Karnofsky performance status &gt; = 60 Patients must recover toxic effect prior therapy : 4 week ( 28 day ) investigational agent , 4 week ( 28 day ) prior cytotoxic therapy , two week ( 14 day ) vincristine , 6 week ( 42 day ) nitrosoureas , 3 week ( 21 day ) procarbazine administration , 1 week ( 7 day ) noncytotoxic agent , e.g. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) ; question relate definition noncytotoxic agent direct study chair WBC &gt; = 2,000/ul ANC &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 10 gm/dl Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 X institutional ULN Creatinine &lt; 1.5 mg/dL Patients must cholesterol level = &lt; 350 mg/dl triglyceride level = &lt; 400 mg/dl Patients must show unequivocal evidence tumor progression MRI CT scan ; scan perform within 14 day prior registration ; type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement Patients must fail prior radiation therapy must interval great equal 6 week ( 42 day ) completion radiation therapy study entry Patients prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease rather radiation necrosis base upon either PET Thallium scanning , MR spectroscopy surgical documentation disease Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : They recover effect surgery Residual disease follow resection recurrent tumor mandate eligibility study ; best ass extent residual disease postoperatively , CT/ MRI do later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day prior registration ; 96hour scan 14 day registration , scan need repeat ; steroid dose increase date imaging registration , new baseline MRI/CT require stable decrease steroid dosage least 5 day PHASE I : Patients may treatment number prior relapse ; relapse define progression follow initial therapy ( i.e . radiation+/ chemo use initial therapy ) PHASE I : For baseline MRI CT scan prior registration , patient Phase I component steroid dose stable least 5 day prior scan ; steroid dose increase date image registration new baseline MR/CT require PHASE II : Patients may treatment 2 prior relapse ; relapse define progression follow initial therapy ( i.e . radiation+/ chemo use initial therapy ) ; intent therefore patient 3 prior therapy ( initial treatment 2 relapse ) ; patient surgical resection relapse disease anticancer therapy institute 12 week , patient undergoes another surgical resection , consider 1 relapse ; patient prior therapy lowgrade glioma , surgical diagnosis highgrade glioma consider first relapse PHASE II : Unstained slide tissue block must available least one prior surgery ; available , frozen tissue also request early surgery PHASE II : Patients eligible participation phase II component study may enrol preoperative study evaluate biological and/or tissue correlate PHASE II : For baseline MRI CT scan prior registration , patient phase II component participate preoperative component study steroid dose stable least 5 day prior scan ; steroid dose increase date image registration new baseline MR/CT require PHASE II : For patient preoperative component , scan show progression require ; scan stable steroid require ; follow surgery , scan do later 96 hour least 4 week surgery steroid dose stable decreasing ; treatment OSI774 ( erlotinib ) CCI779 ( temsirolimus ) postoperatively start later 14 day scan ; 96hour scan 14 day treatment initiate , scan need repeat stable decrease steroid dose Patients must enzymeinducing antiepileptic drug ( EIAED ) ; previously EIAED , patient must least two week prior registration Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible Patients must active infection serious intercurrent medical illness Patients must pregnant/breast feeding must agree practice adequate contraception ; woman childbearing potential must negative BHCG pregnancy test document within 7 day prior registration ; patient must pregnant ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Patients must disease obscure toxicity dangerously alter drug metabolism Patients must receive prior therapy CCI779 ( temsirolimus ) , OSI774 ( erlotinib ) mTOR epidermal growth factor receptor inhibitor HIVpositive patient receive combination antiretroviral therapy exclude study due possible retroviral drug interaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>